Item 8.01 Other Events.
On July 13, 2020, Equillium, Inc. (the "Company") announced that a clinical
trial conducted by its partner, Biocon Limited, demonstrated that itolizumab
significantly reduced mortality in patients hospitalized with COVID-19 in India
and that the Drugs Controller General of India, the regulatory agency that
oversees drug approvals in India, has granted restricted emergency use of
itolizumab for the treatment of cytokine release syndrome in COVID-19 patients
with moderate to severe acute respiratory distress syndrome in India. The
Company, which has the right to develop and commercialize itolizumab in the
U.S., Canada, Australia and New Zealand, is planning to conduct a global
randomized, controlled clinical trial of itolizumab in COVID-19 patients for
which it will file a U.S. investigational new drug application. A copy of the
press release discussing these matters is filed as Exhibit 99.01, and
incorporated by reference in, this report.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibit
Number Description.
99.01 Press release, dated July 13, 2020, issued by Equillium, Inc.
2
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses